To identify limitations of current strategies for intrapartum prophylaxis of neonatal early-onset group B streptococcal infection.
INTRODUCTION
Prevention of neonatal early-onset group B streptococcal infection has been a goal since its emergence in the late 1960s. Several years after the demonstration of the efficacy of intrapartum antibiotic prophylaxis, the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists both embraced the concept but issued different clinical guidelines in 1992. [1] [2] [3] [4] [5] The resultant controversy and implementation difficulties led the Centers for Disease Control and Prevention (CDC) to orchestrate the development of consensus guidelines in 1996 that were embraced by multiple organizations devoted to improving perinatal care. [6] [7] [8] [9] [10] [11] [12] [13] [14] These guidelines advocated the use of either screening for maternal group B streptococcal rectovaginal colonization or clinical risk factors to determine the need for intrapartum prophylaxis. The guidelines also incorporated several modifications to improve the predictive value of screening cultures and to encourage narrow-spectrum antibiotic use to reduce induction of resistance. 14 Recent reports have demonstrated significant reduction in the incidence of early-onset group B streptococcal infection following the institution of guidelines for intrapartum antibiotic prophylaxis. [15] [16] [17] [18] Nonetheless, group B streptococcus remains a leading cause of neonatal early-onset sepsis and infectious mortality among newborn infants in the US. Previous surveys have reported continuing problems in implementation of the consensus guidelines, while other reports have considered the relative merits of increased emphasis on either screening or risk factors. 9, 12, 13, [17] [18] [19] Continuing evaluation of these strategies is essential to improve current practice and to further reduce the residual early-onset group B streptococcal infection-related mortality and morbidity. This report reviews the cases of early-onset group B streptococcal infection at one referral center and its associated hospitals from the time of the initial publication of guidelines for intrapartum chemoprophylaxis in 1992. 4, 5 In doing so, we sought to identify barriers that may potentially be overcome with focused educational or process interventions, and to highlight limitations of intrapartum chemoprophylaxis.
METHODS
All infants admitted to two University of Michigan-affiliated nurseries with culture-proven group B streptococcal disease at 7 days of age or less from July 1992 through December 2001 were identified by review of clinical databases at both institutions. Both received medical neonatology services from the University of Michigan for the duration of the study period. All infants included in this series had group B streptococci recovered from culture of blood or post-mortem lung.
These nurseries serve infants who require specialized care from a large referral area, as well as infants born at the two institutions. Infants who may require extracorporeal membrane oxygenation, inhaled nitric oxide, high frequency ventilation, or other specialized therapies are frequently referred to the University, as are mothers who are at risk of delivering infants who may require neonatal intensive care. Referral patterns did not change substantially during the observation period.
Medical records of all infants and their mothers were reviewed to determine the presence of clinical risk factors for early-onset neonatal group B streptococcal disease (delivery at <37 weeks gestation, rupture of membranes Z18 hours before delivery, intrapartum maternal fever Z381C or 100.41F, maternal group B streptococcal bacteriuria during that pregnancy, or history of prior infant with early-onset group B streptococcal infection) and screening cultures to assess maternal rectovaginal colonization with group B streptococcus (including date and use of selective culture media). Intrapartum prophylaxis was reviewed, including agents employed, dosing frequency, and timing relative to delivery, as well as receipt of other antibiotics within 7 days before delivery. Duration of maternal hospitalization before delivery and the interval from the development of intrapartum risk factors (membrane rupture >18 hours or fever) to delivery were assessed to determine the potential time available for administration of prophylaxis. Age at onset of neonatal signs of early-onset neonatal group B streptococcal disease was recorded, as well as neonatal outcome, including death and requirement for extracorporeal membrane oxygenation. Infants and mothers transferred from outside hospitals routinely had medical records from those facilities sent at the time of transfer. In cases where the infant or mother had been referred from an outside hospital and information was incomplete, telephone contact with the obstetrical care provider and/or the clinical microbiology facility identified by that provider had been made by a neonatology physician, and missing details obtained and recorded.
RESULTS
From July 1, 1992 through December 31, 2001 , 92 infants with culture-proven early-onset group B streptococcal disease were admitted to these two nurseries. Age at onset of symptoms (mean ±SD) was 2.5±1.6 hours. Only one was diagnosed post-mortem (recovery from blood and lung tissue, with consistent pulmonary histologic findings). These infants were born at 23 different institutions in Michigan or Ohio. The annual number of cases ranged from 3 to 17 for the full calendar years, with a generally decreasing trend since 1994 during the study period ( Figure 1 ). Among these infants, 68 received no intrapartum prophylaxis of any duration, while the remaining 24 received a variety of agents and duration of antibiotic therapy. All infants underwent evaluation for infection and empiric treatment with appropriate doses of broad-spectrum antimicrobial agents in the first 24 hours of life.
Early-onset Group B Streptococcal Disease without Intrapartum Prophylaxis
Among the 68 who received no intrapartum prophylaxis, 34 had risk factors for early-onset group B streptococcal infection known hours, nine had intrapartum maternal fever, and two had prior group B streptococcal bacteriuria. None had a previous infant with early-onset group B streptococcal disease. More than one risk factor was present in 10 of these 32 women; in two of these 10, the mother was also known to be colonized with group B streptococcus. One mother whose only risk factor was known rectovaginal colonization 6 weeks prior to delivery refused intrapartum prophylaxis despite extensive discussion, because of concerns about health problems in an earlier sibling that were attributed by the parents to antibiotic therapy. Of the 68 women who received no prophylaxis, 34 (50%) had no clinical risk factors or known colonization, although one of these had intrapartum fetal tachycardia and two had intrapartum symptoms of subsequently confirmed group B streptococcal urinary tract infection. Assessment of maternal group B streptococcal rectovaginal colonization in the 68 who received no prophylaxis had not been performed in 44. A total of 22 women had had rectovaginal cultures for group B streptococcus performed with result known and potentially available. Results were indeterminate at the time of delivery in two women (obtained 24 hours or less before delivery with results not yet available). Among the 22 who had undergone testing for colonization with results potentially available, four were positive. Of the 18 with negative rectovaginal culture, appropriate selective culture media had been used in only six patients and only three of these were obtained within 6 weeks before delivery (at 5, 19, and 20 days before delivery, with the remainder having been obtained 71, 74, and 185 days before delivery). Of the 10 who had nonselective media employed, only four were sampled within 6 weeks of delivery (at 2, 4, 5, and 42 days beforehand, while the remainder were screened 61, 63, 68, 70, 146, and 161 days before delivery). In one noteworthy case, a mother was found to be colonized upon preterm premature rupture of membranes 18 days prior to delivery, and was treated with clindamycin for 7 days. A negative follow-up rectovaginal culture 5 days before delivery prompted a decision to withhold intrapartum antibiotic prophylaxis. Of additional note, the two women with indeterminate screening culture results at the time of delivery had undergone rectovaginal culture using selective media 14 and 24 hours prior to delivery, but neither culture yielded group B streptococcus by the end of a 5-day period of incubation. Including these two women, there were a total of five who had false-negative rectovaginal cultures for group B streptococcus despite adherence to recommended guidelines for sampling time and use of selective media.
Intrapartum prophylaxis was withheld intentionally in the 18 women who had been screened as negative for group B streptococcal colonization (Table 1) , although eight had clinical risk factors and many had not been assessed with selective media or had been screened more than the recommended 6 weeks prior to anticipated delivery. Seven of the 68 receiving no prophylaxis were delivered following attempted medical induction for a variety of indications; four of these were <37 weeks gestation or had ruptured membranes >18 hours but apparently had intrapartum prophylaxis withheld because amniotomy and labor were induced for maternal indications. In another case with ruptured membranes >18 hours but no other evident risk factors, prophylaxis was not given specifically ''to avoid the need for a neonatal sepsis work-up''. One woman who received no intrapartum treatment had received a 10-day course of ampicillin for preterm rupture of membranes that was completed within 7 days of delivery but still delivered an infant with early-onset group B streptococcal disease. Of these 68 women receiving no prophylaxis, 52 were in the hospital for >4 hours (50 for >6 hours) before delivery (range up to 393.5 hours) and theoretically could have received adequate intrapartum antibiotic therapy. Of these 52, 26 had one or more known risk factors (24 with clinical risk factors and two with group B streptococcal colonization only). Of the four with intrapartum fever alone, two first developed the fever 3 hours before delivery (rendering the recommended duration of intrapartum prophylaxis impossible to attain), while the other two had fever noted 4.5 and 5 hours before delivery.
Of the 68 infected infants resulting from these deliveries in which intrapartum prophylaxis was not administered, 14 infants required extracorporeal membrane oxygenation for profound respiratory and hemodynamic failure and three infants died (two of whom had received extracorporeal membrane oxygenation ). All became ill within the first 24 hours of life (mean ± SD: 2.6 ± 1.6 hours). Of the 34 pregnancies with no clinical risk factors or known maternal colonization, six required extracorporeal membrane oxygenation with one death despite extracorporeal membrane oxygenation. Early-onset Group B Streptococcal Disease Despite Intrapartum Prophylaxis Among the 24 mothers who received intrapartum antibiotic prophylaxis of some duration, all received agents in doses expected to be effective against group B streptococcus (ampicillin in 12, ampicillin-sulbactam in two, penicillin in three, cefotetan in one, ceftizoxime in two, and clindamycin in four). All had risk factors (22 clinical, two with known colonization). Of the 22 with clinical risk factors, seven had gestational age <37 weeks by best obstetric estimate, 13 had ruptured membranes Z18 hours, 17 had intrapartum maternal fever, and three were also known to have rectovaginal colonization with group B streptococcus. None of these mothers had prior infants with early-onset group B streptococcal disease or group B streptococcal bacteriuria during the current pregnancy. In all, 17 women had more than one risk factor. Assessment of maternal rectovaginal colonization had not been performed in 18. In the six who underwent sampling, results were positive in five and negative in one.
Of the 24 mothers who received intrapartum prophylaxis, 23 were hospitalized Z4 hours before delivery (range up to 211). Of the six women who had intrapartum fever as the only risk factor, four had the onset of fever >4 hours before delivery. Prophylaxis was received for more than 4 hours (range 4.5 to 31) in nine mothers ( Table 2) . Two of these nine received adjunctive intrapartum antibiotic therapy with other agents as well. All but one of these nine were born with intrapartum maternal fever or prematurity, although four of the nine were asymptomatic until three or more hours after birth. Among these nine there were no deaths, although one infant did require extracorporeal membrane oxygenation.
Less than 4 hours of intrapartum prophylaxis was received by 15 infants (range 0.1 to 3.8 hours), with receipt of ampicillin in six, penicillin G in three, clindamycin in four, ceftizoxime in one, and cefotetan in one. In addition to intrapartum prophylaxis, one had received a single dose of intravenous ampicillin 42 hours before delivery and one received 3 days of parenteral clindamycin within 7 days before delivery. All of the infants became ill within the first 24 hours of life (mean±SD: 2.1±1.3 hours). Two required extracorporeal membrane oxygenation, while one died.
DISCUSSION
Despite the significant reduction in early-onset neonatal group B streptococcal disease and mortality following widespread use of intrapartum prophylaxis, residual cases continue to occur. Such cases result from multiple causes, including (but not limited to) misunderstanding or misapplication of existing guidelines, unavailability of pertinent patient data upon admission to labor and delivery, time limitations (e.g., rapid labor, timing of initiation of intrapartum antibiotics), tissue penetration problems with some antimicrobial agents, 20 maternal refusal of intrapartum prophylaxis, and primary failure of the regimen despite proper implementation. The group presented in this report probably does not include all infants with early-onset group B streptococcal infection in the referral region, since there were likely other infants with such infection at the referring outside hospitals who were not sufficiently ill to require transfer and therefore never came to our attention. Among infants who were inborn or sick enough for transfer, some with early-onset group B streptococcal infection may have been missed because of misleading negative cultures resulting from the inhibitory effects of intrapartum antibiotics. Despite these significant limitations, the study population is large enough to reflect common problems that should be considered if further reduction of early-onset group B streptococcal infection is to be attained. The CDC and others have previously noted problems that could or did lead to nonadministration of intrapartum antibiotic prophylaxis. [6] [7] [8] 10, 12, 14, 17, 19, 21, 22 The most common reason for nonadministration of intrapartum prophylaxis in the present series was unknown colonization status in the absence of clinical risk factors. However, neither the assessment of colonization status nor the presence of clinical risk factors assured intrapartum prophylaxis.
Among those women whose caregivers employed maternal screening for group B streptococcal colonization, we observed multiple cases in which prophylaxis was withheld because of falsenegative screening cultures obtained with nonselective media or long before the 6-week window before delivery when predictive value is higher. 23 The infant with early-onset group B streptococcal infection whose mother did not receive prophylaxis because the second of two cultures for group B streptococcus within the final 18 days before delivery was negative suggests that intrapartum prophylaxis may be warranted if rectovaginal culture is positive within 6 weeks of delivery, despite any subsequent negative studies. The five women in this series who had negative rectovaginal cultures despite selective medium and collection at 14 hours, 24 hours, and 5, 19, and 20 days before delivery illustrate that falsenegative results may occur occasionally despite careful adherence to recommended guidelines for sampling and processing. Other authors have made similar observations. 22 We have insufficient data to project how frequently such false-negative results occur, but can assert that they do occur with adverse outcomes.
The presence of clinical risk factors also did not assure prophylaxis. In a few cases, the time from detection of the risk factor (intrapartum fever, rupture of membranes >18 hours) to delivery may have been too brief to allow intrapartum prophylaxis, while in others antibiotic administration may have been possible but of suboptimal duration to assure protection. Logistical difficulties in the timely administration of antibiotics have been reported in such settings as emergency departments and intensive care units. [25] [26] [27] Similar obstacles probably exist in labor and delivery areas, and may be identified and reduced with careful review and intervention by a team of medical, nursing, pharmacy, clerical, and other involved services. It may be worthwhile to not wait for 18 hours of ruptured membranes before starting intrapartum antibiotic prophylaxis, if it appears that that threshold will be breached. For example, consideration should be given to initiation of prophylaxis at 12 hours after rupture of membranes if delivery is not anticipated within the next 4 hours.
In mothers undergoing induction for maternal indications (usually pre-eclampsia), some clinicians reasoned that prophylaxis was not warranted since labor and subsequent ruptured membranes were not of infectious origin. Nonetheless, seven of the infants delivered solely because of maternal indications developed early-onset group B streptococcal infection. Intrapartum prophylaxis in the case of delivery for purely maternal indications is still warranted in the presence of known clinical risk factors unless delivery is by cesarean section with intact membranes and no labor, in which case infant contact with colonized maternal mucosal surfaces is extremely unlikely.
Perhaps of greater interest are the 24 infants who developed early-onset group B streptococcal disease despite intrapartum antibiotic prophylaxis, especially the nine who had received at least 4 hours and two doses of intrapartum antimicrobial therapy. Many of the 15 with a shorter course of intrapartum prophylaxis had been hospitalized for >4 hours and could have benefited from interventions to facilitate more timely administration of antibiotics. Several of these 15 received nonpenicillins F clindamycin, ceftizoxime, and cefotetan F because of concern about penicillin allergy or desire to provide broader spectrum coverage. The two cephalosporins are known to be 100% effective against group B streptococcus while clindamycin is a recommended alternative for those with penicillin allergy, although reports of resistance in up to 15% of genitourinary group B streptococcal isolates have appeared recently. 29 Early-onset group B streptococcal disease despite intrapartum prophylaxis in cases where agents other than a penicillin are employed may represent incomplete drug distribution, 20 inadequate time for antimicrobial action, or partial treatment of an established fetal infection.
All but one of the nine who received prophylaxis of recommended duration received a penicillin, with the other receiving a cephalosporin that is known to be effective against group B streptococcus. 29 These cases illustrate that early-onset group neonatal B streptococcal disease may occur, even when intrapartum prophylaxis is given in concordance with consensus guidelines. Possible explanations include individual peculiarities in drug distribution or pharmacokinetics, unusually large quantities of bacteria, microenvironmental characteristics at colonized sites that interfere with antimicrobial binding or activity, or the presence of fetal systemic infection before receipt of intrapartum antibiotics. Others have also observed cases of early-onset group B streptococcal disease despite intrapartum prophylaxis with effective agents and appropriate duration. 8, 11, 23, 30 Despite the occurrence of early-onset group B streptococcal disease, it is plausible that outcomes may be better with intrapartum antibiotics (even if less than two doses and 4 hours) than without any antibiotic administration.
Although there has been significant improvement in the frequency and mortality of early-onset neonatal group B streptococcal disease with intrapartum prophylaxis, further refinements are desirable. Educational efforts are warranted to assure that those using the screening approach obtain specimens from proper sites using appropriate media at a time when predictive value is optimal.
14 Results of such screens must be available in labor and delivery when needed. The all too common occurrence of early-onset group B streptococcal disease in the absence of risk factors has prompted the CDC to embrace a strategy combining universal maternal screening and clinical risk factors in their recent revised guidelines for prevention of perinatal group B streptococcal disease (published after the submission and initial editorial review of this manuscript), 31 an approach previously recommended by other authors. 32 Clinical processes to improve timely antibiotic administration should be established whether screening or risk factors are employed for prophylaxis decisions. Induction for purely maternal indications does not preclude the need for prophylaxis in the presence of risk factors unless the woman is known to be negative for group B streptococcus. We attribute at least a portion of the declining cases of early-onset group B streptococcal infection at this institution to continuing educational efforts throughout our region and pointed attempts to overcome identified problems as described above. Early-onset group B streptococcal disease may occur despite appropriate prophylaxis and must still be considered in symptomatic infants. Initiatives to develop a test for group B streptococcal colonization that can be performed rapidly and accurately upon presentation to the labor and delivery unit, the development of effective vaccines against this pathogen, and evaluation of the role of adjunctive postnatal prophylaxis are still warranted and may facilitate further reduction of early-onset neonatal group B streptococcal disease.
